表紙
市場調查報告書

連環蛋白β1:開發中產品分析

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 398834
出版日期 內容資訊 英文 67 Pages
訂單完成後即時交付
價格
Back to Top
連環蛋白β1:開發中產品分析 Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 67 Pages
簡介

本報告提供以連環蛋白β1為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

連環蛋白β1 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Dicerna Pharmaceuticals, Inc.
  • Marina Biotech, Inc.
  • Propanc Health Group Corp
  • Warp Drive Bio, Inc.

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2080TDB

Summary

Catenin Beta 1 (Beta Catenin or CTNNB1) - Catenin beta-1 or B-catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2.

Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 5 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Non Malignant Disorders and Respiratory which include indications Colorectal Cancer, Solid Tumor, Melanoma, Hepatocellular Carcinoma, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Thyroid Cancer, Blood Cancer, Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Endometrial Cancer, Hemangiomas, Hematological Tumor, Hepatic (Liver) Tumor, Idiopathic Pulmonary Fibrosis, Leukemia, Liver Cirrhosis, Lung Cancer, Myelodysplastic Syndrome, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Prostate Cancer.

The latest report Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2019, outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Catenin Beta 1 (Beta Catenin or CTNNB1)
  • The report reviews Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Catenin Beta 1 (Beta Catenin or CTNNB1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Catenin Beta 1 (Beta Catenin or CTNNB1) - Overview
  • Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development
  • Aileron Therapeutics Inc
  • Boston Biomedical Inc
  • Circle Pharma Inc
  • Dicerna Pharmaceuticals Inc
  • Fog Pharmaceuticals Inc
  • iBeCa Therapeutics
  • PRISM Pharma Co Ltd
  • Propanc Biopharma Inc
  • Sapience Therapeutics Inc
  • Venn Therapeutics LLC
  • WntRx Pharmaceuticals Inc
  • Catenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles
  • Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BBI-801 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • exisulind - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Oligonucleotides for Hepatoblastoma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PRI-724 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PRP - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptide for Hematological and Solid Tumor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptide to Inhibit CTNNB1 for Colorectal Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptides to Inhibit Beta Catenin for Solid Tumor and Blood Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VTX-003 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • WX-024 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Catenin Beta 1 (Beta Catenin or CTNNB1) - Dormant Products
  • Catenin Beta 1 (Beta Catenin or CTNNB1) - Product Development Milestones
  • Featured News & Press Releases
  • Oct 21, 2019: Propanc Biopharma illustrates novel mode of action of PRP, suppressing EMT Pathways and Metastasis in Cancer Patients
  • Aug 21, 2019: Propanc Biopharma receives granted US patent covering additional composition claims for PRP
  • Aug 12, 2019: Propanc Biopharma publishes key data in peer reviewed journal confirming anti-cancer stem cell effects of Proenzymes
  • Aug 08, 2019: Propanc Biopharma completes development of bio-analytical assay method to quantify PRP active ingredients in preparation for first-in-human study
  • Jul 15, 2019: Propanc Biopharma provides update on preparation of PRP for clinical trial application submission and recently completed reverse stock split
  • Jun 27, 2019: Propanc Biopharmas Intellectual Property portfolio undergoes rapid growth
  • May 06, 2019: Propanc Biopharma appoints Dr. Ralf Brandt to its scientific advisory board
  • Apr 26, 2019: Announcement of the signing of a joint R & D agreement and commencement of development activities regarding "Research and development of innovative antifibrotic drugs to improve the life prognosis of cirrhosis"
  • Mar 25, 2019: Propanc Biopharma initiates development of bio-analytical assay in preparation for human trials
  • Mar 13, 2019: Propanc Biopharma receives notice of allowance for additional claims from foundation patent in the U.S.
  • Dec 20, 2018: Novel development drug OP-724 (PRI-724) for the treatment of cirrhosis is published on Nature Outline
  • Nov 14, 2018: Adoption as a practical realization development type of the cyclic innovation for clinical empowerment by the Japan Agency for Medical Research and Development
  • Aug 09, 2018: Propanc Biopharma selected to present at the 25th Annual NewsMakers in the Biotech Industry
  • Apr 10, 2018: Propanc Biopharma Completes Scientific Advice Meeting with MHRA
  • Mar 14, 2018: Propanc Biopharma Completes Successful Reproduction Run for PRP
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Aileron Therapeutics Inc, H2 2019
  • Pipeline by Boston Biomedical Inc, H2 2019
  • Pipeline by Circle Pharma Inc, H2 2019
  • Pipeline by Dicerna Pharmaceuticals Inc, H2 2019
  • Pipeline by Fog Pharmaceuticals Inc, H2 2019
  • Pipeline by iBeCa Therapeutics, H2 2019
  • Pipeline by PRISM Pharma Co Ltd, H2 2019
  • Pipeline by Propanc Biopharma Inc, H2 2019
  • Pipeline by Sapience Therapeutics Inc, H2 2019
  • Pipeline by Venn Therapeutics LLC, H2 2019
  • Pipeline by WntRx Pharmaceuticals Inc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top